Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Anasheh Shamirian"'
Autor:
Yael P. Mosse, Brian Weiss, Fariba Goodarzian, Navin Pinto, Judith G. Villablanca, Gregory A. Yanik, Scarlett Czarnecki, Suzanne Shusterman, Araz Marachelian, Anasheh Shamirian, Hiroyuki Shimada, Rachel Berkovich, John M. Maris, Daphne A. Haas-Kogan, Julie R. Park, M. Meaghan Granger, Clare J. Twist, Steven G. DuBois, Lingyun Ji, Kieuhoa T. Vo, Susan L. Cohn, Katherine K. Matthay, Denice D. Tsao-Wei, Kelly C. Goldsmith, Susan Groshen, Meredith S. Irwin
Publikováno v:
J Clin Oncol
PURPOSE 131I-metaiodobenzylguanidine (MIBG) is an active radiotherapeutic for neuroblastoma. The primary aim of this trial was to identify which of three MIBG regimens was likely associated with the highest true response rate. PATIENTS AND METHODS Pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5465588083dc929da824e7729c79092
https://europepmc.org/articles/PMC8547934/
https://europepmc.org/articles/PMC8547934/
Autor:
Thomas Cash, Araz Marachelian, Steven G. DuBois, Yueh-Yun Chi, Susan G. Groshen, Anasheh Shamirian, Alina C Stout, Margaret E Macy, Navin R. Pinto, Ami Vijay Desai, Paul M. Sondel, Shahab Asgharzadeh, Brian D. Weiss, Yael P. Mosse, Katherine K. Matthay, Julie R. Park, Kelly C. Goldsmith
Publikováno v:
Journal of Clinical Oncology. 40:10038-10038
10038 Background: 131I-metaiodobenzylguanidine (MIBG) is one of the most active salvage therapies for patients with relapsed or refractory (R/R) high-risk neuroblastoma (HRNB). Preclinical neuroblastoma studies show cooperative effects when radiation
Autor:
Gregory A. Yanik, Katherine K. Matthay, Yael P. Mosse, Susan L. Cohn, Clare J. Twist, Scarlett Czarnecki, Araz Marachelian, Suzanne Shusterman, Steven G. DuBois, Hiroyuki Shimada, Rachel Berkovich, Susan Groshen, Denice D. Tsao-Wei, Anasheh Shamirian, Julie R. Park, Meredith S. Irwin, Kelly C. Goldsmith, Fariba Goodarzian, Meaghan Granger, Brian Weiss
Publikováno v:
Journal of Clinical Oncology. 38:10500-10500
10500 Background: 131I-metaiodobenzylguanidine (MIBG) remains one of the most active agents for neuroblastoma. It is not clear if putative radiation sensitizers improve upon this activity. The primary aim of this trial was to identify the MIBG treatm
Autor:
Kangning Liu, Charlotte Hasenauer, Michael D. Hogarty, Elizabeth Bruckheimer, Eugene W. Gerner, Andrea T. Flynn, Michelle Haber, Murray D. Norris, Katherine K. Matthay, Susan Groshen, Anasheh Shamirian, David S. Ziegler, Araz Marachelian
Publikováno v:
Journal of Clinical Oncology. 36:10558-10558
10558Background: MYC drives polyamine expansion to support its oncogenic functions. Ornithine decarboxylase (Odc) is a direct MYC target that is rate-limiting for polyamine synthesis, and is itself...
Publikováno v:
Journal of tissue viability. 24(1)
Objective: The SEM Scanner is a medical device designed for use by healthcare providers as part of pressure ulcer prevention programs. The objective of this study was to evaluate the inter-rater and inter-device agreement and reli- ability of the SEM